BioSpace News Archive

Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration

Curebase announced $15M in Series A funding to continue developing its decentralized clinical trial software platform and virtual research site capabilities, powering research where any patient, anywhere, can be part of clinical trials at home and with their own doctor.

Abiomed, Inc., a leading provider of breakthrough heart support technologies, announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at William Blair’s 41st Annual Growth Stock Conference on Tuesday, June 1st at 4:40pm CT and the Jefferies Virtual Healthcare Conference on Thursday, June 3rd at 2:00pm ET.

Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.

Bristol Myers Squibb announced that the company will host a virtual Investor Event on Tuesday, June 8, 2021 at 1 p.m. ET to discuss data presented at the 2021 American Society of Clinical Oncology Annual Meeting.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced that Daphne Zohar, Founder and CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2nd at 9:00 AM EST.

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference.

Senior leadership appointments strengthen VectivBio as it continues development of apraglutide in short bowel syndrome and graft versus host disease, and expansion of its rare disease product portfolio

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will present virtually at two upcoming investor conferences.